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Dear Editor, 
We report a case of an 87-year-old white female presenting with a history of a 
non-tender right orbital swelling. She had subtotal exenteration for unilateral 
Retinoblastoma (RB) at age three followed by Radon seed implantation 
removed 27-years later but received no chemotherapy. 
Although radon seeds were encapsulated in gold tubes allowing gamma-ray 
passage for tumour destruction (whilst blocking alpha and beta particles that 
can risk tissue necrosis), the decay product (210Pb) continued to emit radiation 
for a longer period of time associated with increasing cancer risk, hence the 
use was discontinued after the 1960s.1 
At 82-years-old she was diagnosed with grade-2 invasive ductal carcinoma of 
the left breast (oestrogen receptor-positive subtype). The RB pathway has 
been associated with a less aggressive course in this subtype and non-
heritable RB survivors are more prone to radiation related breast cancer.2,3 No 
genetic testing was available to confirm a germline RB1 or mosaic mutation. 
This case highlights the potential adverse consequence in the radiation field 
with multiple basal cell carcinomas developing over a 20-year period post 
radiation and she also fits the criteria of post irradiation sarcoma described by 
Cahan et al in 1985, which is most commonly encountered 15 years post 
radiation (reported up to 50 years) unlike the present case, where the 
sarcoma occurred 84 years later.4,5,6 
Though there has been a paradigm shift in RB management from radiation to 
chemotherapy, a careful history of previous, now superseded treatments in 
late survivors is mandatory, as is awareness of their very late effects. 
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